Moderna (NASDAQ:MRNA) Shares Down 6.8% – Here’s What Happened

Moderna, Inc. (NASDAQ:MRNA)’s share price dropped 6.8% during mid-day trading on Tuesday. The company traded as low as $250.49 and last traded at $250.83. Approximately 11,102,965 shares changed hands during trading, a decline of 12% from the average daily volume of 12,638,438 shares. The stock had previously closed at $269.00.

Trending Headlines about Moderna

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Moderna reported third-quarter revenue of about $1.3 billion, up 29% year over year, and raised its full-year 2026 revenue-growth forecast to 15%–25%. Lower costs and gains from respiratory vaccines also supported the improved outlook. Why is Moderna (MRNA) stock soaring today
• Positive Sentiment: Investors are also watching intismeran, Moderna’s personalized cancer therapy. Phase 3 data showed a 42% reduction in melanoma recurrence or death; the company is targeting an FDA filing by year-end 2026, with a possible decision in 2027. Moderna: 3 Key Takeaways for Long-Term Investors
• Neutral Sentiment: Moderna will present at the Jefferies Global Health Care Conference on November 18. The event may provide an update, but the announcement itself does not change the company’s outlook. Moderna to Present at Upcoming Conference in November 2026
• Negative Sentiment: Valuation is a key risk after the stock’s sharp run-up. Goldman Sachs raised its target to $195 but kept a neutral rating, while commentary argues that much of the expected sales growth may already be priced in. Goldman Sachs price-target update Moderna’s Q3 Numbers May Have Seemed Impressive, but They Aren’t Enough to Make the Stock a Buy
• Negative Sentiment: Despite the improved quarter, nearly all of Moderna’s revenue still comes from COVID-related products, leaving the company reliant on diversifying successfully into oncology and other areas. Moderna’s Q3 Numbers May Have Seemed Impressive, but They Aren’t Enough to Make the Stock a Buy

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the stock. William Blair cut shares of Moderna from an “outperform” rating to a “market perform” rating in a research note on Tuesday, October 27th. TD Cowen restated a “buy” rating on shares of Moderna in a research report on Wednesday, October 21st. Morgan Stanley upped their target price on shares of Moderna from $89.00 to $95.00 and gave the company an “equal weight” rating in a report on Wednesday, October 7th. Barclays boosted their price objective on shares of Moderna from $48.00 to $125.00 and gave the company an “equal weight” rating in a research report on Monday, August 24th. Finally, Bank of America upped their price objective on Moderna from $170.00 to $200.00 and gave the stock a “neutral” rating in a research note on Friday, October 9th. Six investment analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and four have issued a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $113.75.

Moderna Stock Performance

The company has a market cap of $100.14 billion, a P/E ratio of -35.33 and a beta of 1.16. The business’s 50 day simple moving average is $194.47 and its 200 day simple moving average is $92.61. The company has a current ratio of 2.29, a quick ratio of 2.18 and a debt-to-equity ratio of 0.09.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings results on Friday, November 6th. The company reported $0.38 earnings per share for the quarter, topping analysts’ consensus estimates of ($1.10) by $1.48. The business had revenue of $1.31 billion during the quarter, compared to analyst estimates of $890.25 million. Moderna had a negative net margin of 141.43% and a negative return on equity of 28.30%. The company’s revenue was up 29.2% on a year-over-year basis. During the same period in the prior year, the business posted ($0.51) earnings per share. Sell-side analysts predict that Moderna, Inc. will post -6.11 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Moderna news, insider Shannon Klinger sold 3,471 shares of the firm’s stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $139.95, for a total transaction of $485,766.45. Following the sale, the insider directly owned 74,129 shares of the company’s stock, valued at $10,374,353.55. This trade represents a 4.47% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO James M. Mock sold 34,836 shares of the business’s stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $134.49, for a total value of $4,685,093.64. Following the completion of the transaction, the chief financial officer owned 59,375 shares in the company, valued at $7,985,343.75. The trade was a 36.98% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 197,251 shares of company stock valued at $33,875,904. Company insiders own 10.80% of the company’s stock.

Institutional Trading of Moderna

Several institutional investors and hedge funds have recently added to or reduced their stakes in MRNA. BlackRock Inc. bought a new position in Moderna in the 2nd quarter worth approximately $2,142,877,000. Theleme Partners LLP bought a new stake in shares of Moderna during the second quarter valued at approximately $564,272,000. Wellington Management Group LLP lifted its holdings in shares of Moderna by 4.4% in the second quarter. Wellington Management Group LLP now owns 2,461,574 shares of the company’s stock worth $172,384,000 after buying an additional 103,977 shares in the last quarter. First Trust Advisors LP lifted its holdings in shares of Moderna by 59.3% in the first quarter. First Trust Advisors LP now owns 2,392,693 shares of the company’s stock worth $121,549,000 after buying an additional 891,072 shares in the last quarter. Finally, Merck & Co. Inc. bought a new position in shares of Moderna during the second quarter worth $161,642,545. Institutional investors own 75.33% of the company’s stock.

About Moderna

Moderna, Inc. is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease. The company’s commercial products include Spikevax, a vaccine against COVID-19, and mRESVIA, a vaccine against respiratory syncytial virus (RSV). Moderna also researches potential mRNA-based vaccines and treatments for infectious diseases, cancer, and rare diseases. Founded in 2010 as Moderna Therapeutics, the company is headquartered in Cambridge, Massachusetts.